Drug Approval

Showing 351 articles
Business

AbCellera Biologics: A Valuation Crossroads After Volatile Returns

Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.

Business

Nvidia Aided China's DeepSeek In Advancing Powerful AI Models Later Linked To Military Use, House Committee Chair Alleges: Report

A U.S. lawmaker has alleged that Nvidia Corp (NASDAQ:NVDA) provided technical assistance to Chinese AI startup DeepSeek. Nvidia Technical Support Allegedly Boosted DeepSeek's Efficiency Nvidia helped DeepSeek improve the efficiency of its artificial intelligence models, according to a letter sent to the U.S. Commerce Department by Rep. John Moolenaar (R-Mich.), chair of the House Select Committee on China. The letter, seen by Reuters on Wednesday, says documents obtained by the committee show th

Business

SuperX AI Soars 48% in a Week, Delivering Windfall for Major Private Backers

A dramatic surge in SuperX AI Technology's share price has spotlighted its concentrated ownership structure, with private companies holding a dominant 34% stake and reaping the largest rewards from the recent rally. As the AI-driven healthcare sector heats up, investor attention turns to who holds the reins at this promising but closely held firm.